Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche CD47 antibody start-up gives up-lays off all employees

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 17, 2024 12:30pm

103 Views

Post# 36045720

RE:Roche CD47 antibody start-up gives up-lays off all employees

May 17, 2024 - An early data abstract on Shattuck Labs’ anti-CD-47 SL-172154, released yesterday at the upcoming European Hematology Association conference, has reported waning efficacy, a heart attack, and a death.

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program